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Background: High-level disinfection protects tens-of-millions of patients from the transmission of viruses on
reusable medical devices. The efficacy of high-level disinfectants for preventing human papillomavirus (HPV)
transmission has been called into question by recent publications, which if true, would have significant pub-
lic health implications.
Methods: Evaluation of the clinical relevance of these published findings required the development of novel
methods to quantify and compare: (i) Infectious titres of lab-produced, clinically-sourced, and animal-
derived papillomaviruses, (ii) The papillomavirus dose responses in the newly developed in vitro and in vivo
models, and the kinetics of in vivo disease formation, and (iii) The efficacy of high-level disinfectants in inacti-
vating papillomaviruses in these systems.
Findings: Clinical virus titres obtained from cervical lesions were comparable to those obtained from tissue
(raft-culture) and in vivo models. A mouse tail infection model showed a clear dose-response for disease for-
mation, that papillomaviruses remain stable and infective on fomite surfaces for at least 8 weeks without
squames and up to a year with squames, and that there is a 10-fold drop in virus titre with transfer from a
fomite surface to a new infection site. Disinfectants such as ortho-phthalaldehyde and hydrogen peroxide,
but not ethanol, were highly effective at inactivating multiple HPV types in vitro and in vivo.
Interpretation: Together with comparable results presented in a companion manuscript from an independent
laboratory, this work demonstrates that high-level disinfectants inactivate HPV and highlights the need for
standardized and well-controlled methods to assess HPV transmission and disinfection.
Funding: Advanced Sterilization Products, UK-MRC (MR/S024409/1 and MC-PC-13050) and Addenbrookes
Charitable Trust





Methodology for virus infection assay
High-level disinfectantm.2020.103165.
V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)1. Introduction
Human papillomaviruses (HPVs) cause a diverse range of skin
lesions, from common or genital warts, to high-grade neoplasia.
High-risk HPV-driven neoplasia can result in the development of sev-
eral human cancers, of which cervical cancer is the most prevalent.
Current HPV vaccines are not therapeutic [1], uptake has been vari-
able (as low as 40% in the US and France) [2,3], and there remains no
targeted antiviral therapy that can clear HPV-associated disease post-infection. High-risk HPVs are typically transmitted by close physical
contact, but are stable in the environment and can be transmitted
indirectly [4], either as free virions or as virus-laden epithelial cells
(squames) from fomite surfaces such as medical devices [5,6]. This is
true of transvaginal ultrasound probes, cryotherapy tips, thermal
ablation probes and speculums, which if contaminated with high-
risk HPV can facilitate virus transmission to the most vulnerable site
of the body, the cervical transformation zone [7].
To date, there have been few studies addressing the susceptibility
of HPV to clinical disinfectants, and as a consequence, the efficacy of
disinfectants to inactivate HPV has been extrapolated from the use of
surrogate non-enveloped viruses such as poliovirus [8], or through
the use of surrogate papillomavirus particles that are produced in
vitro (i.e. pseudoviruses and raft-cultured viruses). This is primarily
Research in Context
Evidence before this study
Questions had been raised about the effectiveness of high-level
disinfectants such as ortho-phthalaldehyde based on data with
raft cultured HPV16 and 18 using in vitro infectivity assays. The
work has not been reproduced by any other laboratories and
there are multiple methodological and translational gaps that
would need to be addressed to evaluate the reproducibility and
clinical relevance of these data. The gaps include an under-
standing of:
 Levels of HPV titres in clinically derived human lesions to
know whether the levels being tested in model systems
(e.g. raft tissue-derived and pseudovirus titres) were rele-
vant to humans
 Similarities and differences in clinically sourced virus
titres across different HPV high risk (e.g. cervix) and low
risk lesions (e.g. anogenital and laryngeal)
 How to consistently and objectively evaluate the lowest
infectious dose required to achieve infection (not cap-
tured by VGE/cell) and compare across viral preparations
 Effect of squames on infectivity across in vitro and in vivo
models
 Differences in infectivity of raft tissue-derived, pseudovi-
rus, and in vivo sources viruses
 Viral titres that can be transferred from a lesion to a
fomite surface
 Effect of squames on viral survival over time on a fomite
surface
 Dose-response and kinetics of infection in an in vivo
model and its relation to results in in vitromodels
 Impact of neutralizing agents on viral infectivity
 Impact of virus isolation technique from raft culture on
the infectivity readout
 Impact of timing for readouts on infectivity in vitro
In order to evaluate the relevance of the clinical results it
was necessary to develop novel translational methods to
address the above gaps.
Added value of this study
The work presented in this publication together with work pre-
sented in the companion manuscript by the lab of Dr. Michelle
Ozbun (https://doi.org/10.1016/j.ebiom.2020.103165) have
addressed the gaps listed above. They have advanced our
understanding of the in vitro to in vivo correlation for papillo-
mavirus (PV) infectivity and have provided key insights on how
to design infectivity and disinfection testing studies that have
greater clinical relevance. The results have also demonstrated
that high level disinfectants such as ortho-phthalaldehyde and
hydrogen peroxide are effective at inactivating HPV on fomite
surfaces that are representative of surfaces on medical devices.
The publications that called this into question had methodo-
logic issues related to their neutralizing agent that may have
confounded their results.
Implication of all the available evidence
The data generated allow the healthcare community to have
confidence in the use of disinfectants such as ortho-
phthalaldehyde and hydrogen peroxide to disinfect medical
devices and thereby protect patients against HPV transmission.
The methods that have been developed, which combine quanti-
fication of viral load in patient lesions, with in vitro cell culture
across multiple viral subtypes and in vivo testing with rigorous
controls, provide a helpful framework for evaluating new thera-
peutic and disinfectant agents against other virus types.
2 N. Egawa et al. / EBioMedicine 63 (2021) 103177due to the difficulties of producing high titres of infectious HPV par-
ticles in vitro, and the lack of a suitable assay to quantify infection, as
HPVs do not cause cytopathic effects (CPE) or drive cell lysis in mono-
layer assays. The extent to which these assays and infection models
mimic in vivo infection and the transmission via squames of clinically
relevant HPV titres is uncertain [9,10].
Recently, there have been several publications from a single
research group suggesting that certain high-level disinfectants may
be ineffective in preventing HPV transmission from medical devices,
based on an in vitro infectivity model using crude HPV preparations
from organotypic (raft) culture [11,12]. Given these implications for
public health, the objective of this work was to evaluate the clinical
relevance and validity of these findings, which required the develop-
ment and use of novel methods and models to quantify and compare:
(i) Infectious titres of in vitro lab-produced, clinically-sourced (from
patient cervical lesions), and animal-derived viruses, (ii) The dose-
response and the kinetics of disease formation in these newly devel-
oped in vitro and in vivo models, and (iii) Efficacy of high-level disin-
fectants in inactivating PV in these systems. This work has provided
key insights on the ‘viral load’ and potential infectious titre observed
clinically, differences in infectivity between raft-derived viruses and
in vivo derived viruses, the potential impact of disinfection neutraliz-
ing agents used as controls, and their interaction with the virus dur-
ing infectivity assays, and the role of the exfoliating cells (or




The collection of clinical material used in this study complied with
the Helsinki Declaration of 1975, as revised in 1983, and was
approved by an independent ethics committee (South Central Oxford
B, 17/SC/0203) as per UK regulations.
2.2. Collection of patient HPV from cervical lesions
To evaluate the levels of HPV virions present in the surface layer of
cervical lesions from patients with high-risk HPV (hrHPV) infection, a
nitrocellulose membrane (254 mm diameter, GE Healthcare, Illinois,
United States) was applied to the cervix for a contact time of 15 s,
transferring surface cells and virus particles onto the membrane
(patch sample). A total of 40 samples were collected from patients
attending Cambridge University Hospitals between 2018 to 2019.
2.3. Typing and quantification of HPV on the membrane
Membranes were fixed with 4% paraformaldehyde, then permea-
bilised with 0.1% Triton X-100. Following Benzonase (Sigma-Aldrich,
Missouri, United States) treatment at 37°C for 1 h (leaving only the
potentially infectious encapsidated viral genome DNA), total DNA
was extracted. Samples were typed and quantified using the high-
risk Human Papillomavirus (HPV) Genotyping Real Time PCR kit
(Shanghai ZJ Bio-Tech, Shanghai, China), using reference HPV
genomes obtained from The International Human Papillomavirus
Reference Centre as standards.
N. Egawa et al. / EBioMedicine 63 (2021) 103177 32.4. Production of papillomavirus
We employed three systems to produce/obtain infectious PV par-
ticles. Recombinant-based HPV16 pseudovirions (PsV) with reporter
plasmid pCMV-Gluc2 (New England Biolabs, Massachusetts, United
States) were produced using 293TT cells (RRID: CVCL_1D85) and
p16sheLL (RRID: Addgene_37320) [1315]. Organotypic raft culture-
derived HPV18 was produced using NIKS cells (a spontaneously
immortalised human keratinocyte cell line) and HPV18 genome
[1618]. Mus musculus PV type 1(MmuPV1) was extracted from
mouse lesions [19]. Tissue homogenates and cell lysates were incu-
bated at 37°C with Benzonase for 24 h. After a low-speed centrifuga-
tion step to remove cellular debris, the virus particles were pelleted
by ultracentrifugation then resuspended with PBS with 10% FBS (cell-
free virus) [20]. For MmuPV1 on fomites, virus with exfoliating cells
on the lesion surface, was transferred onto the tip of a 3 mm diameter
acrylonitrile butadiene styrene (ABS) stick (virus with exfoliating
cells). Alternatively, 2 mL of cell-free virus (2 £ 108 VGE) was placed
onto the tip of the stick and left to dry for 1 h. The virus on fomite
(ABS stick) was kept at room temperature (2024°C) and 4565%
relative humidity (dark and no contact with circulating air).2.5. Quantification of viral genome equivalents (VGE)
VGE represents the level of encapsidated viral DNA. Virus genome
copy number was determined by SYBR Green qPCR (Thermo Fisher
Scientific, Massachusetts, United States) using type-specific primers
(Supplementary Table 1).2.6. Antibodies
Antibodies used included rabbit anti-MmuPV1 L1 and E4 (devel-
oped in the lab, 1:200 for immunofluorescence), and mouse anti-
HPV18, HPV-16 and MmuPV1 neutralising antibodies (which were a
gift of Neil Christensen, Pennsylvania State University College of
Medicine, 1:200 for neutralising assay) [2123].2.7. Virus infectious titre in vitro (quantification of virus transcripts)
The infectious titre of PV in vitro is described as the quantity
of virus E1^E4 transcripts or Gaussia Luciferase (GLuc) reporter
gene activity. HaCaT cells (RRID: CVCL_0038), which were cul-
tured in Dulbecco Modified Eagle Medium (2 £ 105cells/well in
6-well plates), were infected with the virus in the presence or
absence of the neutralising antibody. After 24 h, the medium was
exchanged, and the cells were incubated for a further 24 h before
the cells or culture media were collected. The activity of GLuc in
the media was measured using the Gaussia Luciferase Assay
Kit (New England Biolabs). Following total RNA extraction and
first-strand cDNA synthesis, virus E1^E4 was also quantified by
SYBR Green qPCR using type-specific primers (Supplementary
Table 1).2.8. Infectious foci assay
Viral transcripts in individually infected HaCaT cells were
detected and visualised using RNAscope in situ hybridization
(Advanced Cell Diagnostics, Minnesota, United States) following
the manufacturer’s instruction. The probe used for MmPV1 RNA
detection was MusPV-E6-E7 (Cat No. 409771), and the probe
used for HPV18 RNA was HPV-HR18 (Cat No. 312591). The pro-
portion of virus RNA-positive cells was quantified and the multi-
plicity of infection (MOI) was determined by inverse Poisson
distribution[24].2.9. Quantification of MmuPV infectivity in vivo
All animal procedures were conducted in accordance with the
Animals (Scientific Procedures) Act 1986 and in compliance with the
ARRIVE guidelines. The protocols were approved by Animal Welfare
and Ethical Review Body (AWERB) of the University of Cambridge
and the Home Office (the project licence number: 70/8113).
Tails of athymic nude mice (Hsd:Athymic Nude-Foxn1nu, female,
68 weeks of age, after a week of acclimatisation; ENVIGO, Indianap-
olis, United States) were inoculated with different doses (in 2 mL vol-
ume) of cell-free MmuPV1 following a 3 mm long scarification of the
epidermis (up to 3 inoculation sites per a mouse tail), then observed
at weekly intervals for 16 weeks for the appearance of palpable/visi-
ble lesions. The sample size (the number of inoculation sites of each
group were between 10 and 33 (specified in Figures). The percent of
infected sites with lesions was plotted as a reverse Kaplan-Meier
curve. The statistical significance is shown using the log-rank test.
The sample size was determined using the outcomes shown in
Fig. 3a. In this study, in vivo experiments were conducted by two per-
sons but not randomised. Potential confounders such as the order of
treatments and measurements, or animal/cage location were not
controlled. There were no exclusions of animals during the experi-
ments.
2.10. Disinfection assay
2mL of virus sample, which contains 10% of FBS as an organic load
(soil), was incubated with 8 mL of each disinfectant (0.55% ortho-
phthalaldehyde (OPA, Advanced Sterilization Products, California,
United States), 30% hydrogen peroxide (Sigma-Aldrich), 1000/
5000 ppm hypochlorite (Advanced Sterilization Products) or 70% eth-
anol) for 12 minutes at room temperature (<25°C). 80% of each disin-
fectant as working concentration was chosen in light of the European
Standard for the quantitative suspension test for the evaluation of
virucidal activity [8]. The contact time (12 min) was chosen as speci-
fied by the manufacturer of OPA for comparison. Hypochlorite and
hydrogen peroxide were subsequently neutralised by adding 90 mL
1% cysteine/peptone (for hypochlorite) and 200 units/mL catalase
(for hydrogen peroxide) in DMEM supplemented with 10% FBS for
1 h. OPA was neutralised by adding 10 mL 10% glycine or lysine for
10 min, then incubated for 50 min in 80 mL DMEM + 10% FBS. Next,
100 mL of disinfectant- or neutralised disinfectant-treated virus was
added to 2 mL culture medium for infection. For these in vivo model,
2 mL of disinfectant- or neutralised disinfectant-treated virus was
used for inoculation. For virus on fomites, the tip of the fomite (ABS
stick) was incubated with 1 mL of each disinfectant (80% as working
concentration) for 12 min at room temperature (<25°C), then incu-
bated with 1 mL of neutralised disinfectant for 10 min, twice. Mice
were then inoculated with the treated virus. Virus incubated with
neutralised disinfectant was used as control.
2.11. Evaluation of neutralised OPA and virus charge
For neutralised OPA, 2mL neutralised OPA (glycine- or lysine-HCl)
was diluted with 1 mL 20 mM HEPES (pH 7.4), then passed through a
Sartobind S or Q pico ion exchange membrane (Sartorius, G€ottingen,
Germany) following equilibration with 20 mM HEPES. The flow-
through was collected, and OPA-glycine and OPA-lysine were quanti-
fied via spectrometer by measuring absorbance at 220 nm. This mea-
surement was subtracted from the input, and the result was given as
the amount of neutralised OPA sequestered to the membrane. For
virus, 2 mL virus sample with/without 98 mL neutralised OPA was
diluted with 1 mL 20 mM HEPES, then passed through an ion-
exchange membrane following equilibration. The membrane was
washed twice with 1 mL 20 mM HEPES. Virus sequestered to the
membrane was eluted with 1 mL 20 mM HEPES/0.5 M NaCl. The
4 N. Egawa et al. / EBioMedicine 63 (2021) 103177buffer was exchanged to PBS using a Zeba Spin Desalting Column,
40K MWCO (Thermo Fisher Scientific), and the sample was subject to
subsequent analyses. The pI and charge of neutralised OPA was esti-
mated using SPARC online calculator [25].
2.12. Statistics
Data are given as means § standard deviation (SD). For compari-
son of two groups (Fig. 1b), Mann Whitney test was used (two-
tailed). Percent of infected sites with lesions was plotted as a reverse
Kaplan-Meier curve (Fig. 3 and 7). For comparison of two groups, the
log-rank test was used.
2.13. Role of Funding Source
This work is supported by Advanced Sterilization Products (ASP)
and UK-MRC (MR/S024409/1 and MC-PC-13050), Addenbrookes
Charitable Trust. ASP had no role in study design, data collection and
data analysis but provided input on interpretation and proofreading
of the manuscript (Jeremy Yarwood, Marc Rogers, Ankur Sharma,
Gary Eichenbaum are listed as authors). UK-MRC and Addenbrookes
Charitable Trust have no role in study design and data collection,
data analysis, interpretation or writing of the manuscript. Adden-
brookes Charitable Trust funded Aslam Shiraz PhD programme.
Advanced Sterilization Products funded part of Aslam Shiraz PhD pro-
gramme and paid for the work done in this study including the in vivo
work. UK Medical Research Council (sponsor reference MC-PC-13050
& MR/S024409/1) funded Prof. John Doorbar’s lab and Taylor Saun-
ders-Woods PhD programme.
3. Results
3.1. Quantitation of viral genome equivalents in the exfoliating cell
layers of the cervix from patients with HPV
A ‘patch-sampling’ approach was used to collect exfoliating cervi-
cal cells from women attending for routine colposcopy (Fig. 1a), and
the titre of viral genome equivalents (VGE) per mm2 of surface epi-
thelium was quantified (from 40 patients (one patch per patient)),
Figure 1c. VGE is a measure of encapsidated viral genomes or ‘virus
particles', and is distinct from the more commonly used term ‘viral
load’, which counter-intuitively is a measure of HPV DNA abundance,
irrespective of whether genomes are packaged, present as free epi-
somes, or integrated into the host cell chromosome. Most patients
were positive for multiple HPV types using the VGEVGE assay. Among
these patients, a single HPV type (shown in red in Fig. 1c) was found
to contribute most (>90%) to the overall titre. In individuals where
only a single HPV type was detected, HPV16 was present in 81.2% (9
of 11 cases) of individuals, albeit at low titres (<1 £ 104 VGE/mm2).
Amongst those with the most productive low-grade squamous intra-
epithelial lesion (LSIL) (i.e., those with titres >1 £ 107 VGE/mm2,
Fig. 1c shadowed in grey), HPV18 was the predominant type (37.5%,
3 of 8 cases). Regions of high-grade neoplasia were often accompa-
nied by low-grade disease (33% of high-grade squamous intraepithe-
lial lesion (HSIL) cases also contained LSIL), which is reflected in the
wide range of titres in the samples (1.27 £ 106 VGE/mm2 to
1.45 VGE/mm2 in HSIL alone; 9.72 £ 108 VGE/mm2 to 0.339 VGE/
mm2 in LSIL alone).
3.2. Measuring HPV infectious titre using ‘transcript quantitation’ and
‘infectious centre’ assays
For these experiments, high-risk HPV virions at clinically relevant
titres were prepared from the differentiated layers of organotypic
raft cultures. Although several high-risk HPV types can be propagated
in raft culture[16], HPV18 was used as it was the predominant typefound in productive LSILs (>1 £ 107 VGE/mm2, Fig. 1c). Parallel infec-
tivity studies were carried out using high-risk HPV PsV and MmuPV1.
Viral E1^E4 transcript abundance for HPV18 and MmuPV1, and
reporter gene activity for PsV, were in all cases proportional to the
infecting virus (VGE) dose in HaCaT cells (Figs. 2a and 2b). The
approach had high detection sensitivity and could reveal the extent
of infection at VGE titres as low as 1.0 £ 102/cell, as well as showing
a wide dynamic range (>5 log10), a characteristic that is required for
the evaluation of inhibitory agents targeting the infection process.
For both HPV18 and MmuPV1, the pre-incubation of virions with
anti-L1 neutralising antibodies abolished detectable infection
(Figs. 2a and 2b)b. The infectious centre assay was more laborious
and less sensitive, with a detection threshold of 50 VGE/cell. Human
papillomavirus infection of monolayer keratinocytes is not associated
with cytopathic effect (CPE) and is not productive, which limits infec-
tious centres to the initially infected cell and its immediate daughter
cells (Figs. 2cc and 2d). Both HPV18 and MmuPV1 were, however,
found to have similar particle/infectivity ratios in this assay, with
around one infectious event per 450 VGE (Figs. 2cc and 2d).
3.3. The kinetics of papillomavirus disease formation in vivo;
correlation with in vitro assays
To establish the in vivo relevance of the cell-based assays and
patient-derived titres, PV viral load, fomite transmission and infec-
tivity was evaluated using the MmuPV1 mouse model. After tail
scarification and inoculation with a range of MmuPV1 titres reflect-
ing those seen in clinical lesions (see Fig. 1 and Supplementary
Figure 1), athymic nude mice were monitored weekly for the
appearance of palpable/visible lesions. The disease was apparent
between weeks one and fourteen post-infection, with the timing of
lesion appearance being directly proportional to the inoculation
dose (Figs. 3a and 3b) as demonstrated in the in vitro assays (Fig. 2).
The limit of in vivo detection was 2.0 £ 103 VGE, with the infectious
disease model having a dynamic range of approximately 6 log10 of
virus dose. This data indicates that the rate of in vivo lesion forma-
tion is influenced by the virus titre, and when considered alongside
the in vitro data, suggest that this reflects the number of initiating
infection events.
3.4. Role of exfoliating cells in modulating the papillomavirus in vivo
infectivity
During natural transmission, papillomaviruses are shed and trans-
mitted within exfoliating cells or squames [26], and although the
transmission vehicle is thought to modify virus survival and infection
kinetics, this remains to be addressed in relation to disease develop-
ment. To examine this, virus collected on fomites from in vivo
infected MmuPV1 lesions was quantified using the VGE assay, fol-
lowed by an assessment of virus transfer-efficiency to uninfected
skin. Fomites that had direct lesional contact showed a median virus
titre of 5.2 £ 106 VGE/mm2, which is towards the upper end of what
was seen for HPV at the cervical surface (Fig. 1). One log10 reduction
in VGE titre (median 5.1 £ 105/mm2) occurred following fomite-
mediated transfer to new sites of infection (Supplementary Figure 2),
with the infectivity of ‘virus with exfoliated cells’ being similar to
that seen with ‘cell-free’ virus at titres of 2.0 £ 106 VGE to 2.0 £ 107
VGE per site (Fig. 3c). As papillomaviruses are thought to be relatively
stable in the environment [4], next we examined the role of the exfo-
liated cell in modulating virus desiccation sensitivity. Although infec-
tious immediately after deposition on fomites, cell-free virus lost
viability in the in vivo assays upon storage, with a >3 log10 reduction
in titre after 8 weeks at room temperature (Fig. 3c). In contrast, virus
collected with exfoliating cells showed minimal loss of infectious via-
bility over this period, and surprisingly showed no significant drop in
infectivity even after 52 weeks of desiccation at room temperature
Fig. 1. Variation in human papillomavirus VGE titres at the surface of the cervix
(a) Exfoliating cells from 40 patients were collected from the surface of the cervix using a nitrocellulose patch (see Methods). (b) After Benzonase digestion to remove non-
encapsidated viral DNA, quantitative HPV typing was carried to determine virus type and titre (VGE/mm2; Y-axis). For each patient, associated disease was classified either as LSIL
(blue), HSIL (red), or as encompassing both HSIL and LSIL together (yellow). p = 0.058, LSIL versus HSIL (Mann Whitney test). (c) Detail of HPV types and VGE abundance in LSIL and
HSIL are shown. Virus titre in the exfoliating cervical cells of the cervix of 40 different patients are shown as VGE/mm2. HPV types detected at the lesion surface are listed, with the
most prominent HPV type in each case highlighted in red and virus titres.
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Fig. 2. Quantification of virus infectious titre in vitro
(a, b) Measurement of E1^E4 viral gene transcripts or Gaussia luciferase reporter gene activity in HaCaT cells infected with differing doses of HPV18 (red), MmuPV1 (green) and
PsV (black). Infectious titre shown with 5-6 log10 dynamic range. Neutralising assay compares virus titre following incubation with the neutralising antibody or isotypic control. AU,
arbitrary unit; NT, not tested; ND, not detected. Data is obtained with biological triplicates and shown as Mean and SD. (c, d) RNAscope visualisation of E6 and E7 viral gene tran-
scripts in HaCaT cells infected with HPV18 (top) or MmuPV1 (bottom); virus titre shown as VGE/cell; proportion of virus-RNA positive cells (cell boundary in red) given as %.; boxed
regions enlarged in (d). Scale bar; 100mm
6 N. Egawa et al. / EBioMedicine 63 (2021) 103177(Fig. 3c). These results suggest that papillomaviruses are extremely
stable when shed from lesional surfaces, and that exfoliating cells
facilitate papillomavirus survival in the environment. When taken
together, this data also suggests that the risk of in vivo disease forma-
tion may be extrapolated from in vitro test results (Fig. 4).
3.5. In vitro efficacy of disinfectants in controlling papillomavirus
transmission
In in vitro assays, both HPV18 and MmuPV1 were found to be sim-
ilarly susceptible to both aldehyde-based cross-linking agents and
oxidizing agents (OPA, hydrogen peroxide and hypochlorite). These
are the two most widely used disinfectant classes, and in both cases,
the observed >4-log10 reduction in infectivity (Fig. 5a) exceeds cur-
rent EU and FDA guidelines regarding the suitability of disinfectants
for use in high-level disinfection [8]. In agreement with previous
results, ethanol showed no ability to abrogate papillomavirusinfectivity. Similar results were obtained with the pseudoviruses,
except in the case of ethanol which conferred a one log10 infectivity
reduction (Fig. 5b).
An important finding in the disinfection testing was that OPA
that had been neutralised with glycine (subsequently referred to
as OPA-glycine, see Fig. 6), which is the standard negative control
for evaluating OPA efficacy, was also able to inhibit papillomavi-
rus infectivity in the in vitro assay (Fig. 6a), whereas OPA neutral-
ised with lysine (subsequently referred to as OPA-lysine) showed
no inhibitory activity (Figs. 5 and 6a). OPA-glycine and OPA-lysine
differ in overall charge at neutral pH (Fig. 6b), raising the hypoth-
esis that a transient electrostatic association between OPA-glycine
and positively charged PV particles may underlie the observed
infectivity reduction, as reported for other negatively charged
molecules, such as carrageenan [15]. In support of this hypothe-
sis, neat OPA-lysine, which has a slight positive charge, and the
negatively charged neat OPA-glycine were differentially
Fig. 3. Quantification of virus infectivity in vivo using MmuPV1 model
(a) Proportion of lesions formed at infected sites over a 16-week post-inoculation observation period with differing virus doses. * indicates p < 0.05, **indicates p < 0.01 (the
log-rank test). The numbers of sites of inoculation (N) and mice in each group are shown. (b) Number of weeks until appearance of first lesion post-inoculation at differing virus
doses are shown as Mean and Range. The numbers of sites of inoculation and lesion formed are shown. (c) Proportion of lesions formed at infected sites over a 16-week post-inocu-
lation observation period for either virus with exfoliating cells on fomite (kept for 0, 8 and 52 weeks) or cell-free virus on fomite (kept for 0 and 8 weeks). Fig. 3a results are shown
for comparison, in grey. **indicates p < 0.01 (the log-rank test). The numbers of sites of inoculation (N) and mice in each group are shown.
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Fig. 5. Evaluation of disinfectant efficacy using in vitro infection assay
(a, b) Measurement of viral infectivity (E1^E4 viral gene transcripts or reporter gene activity shown as Mean and SD) of HPV18, MmuPV1 and PsV in HaCaT cells following incu-
bation with viruses treated with disinfectants or their neutralised equivalent (except 70% ethanol). AU, arbitrary unit; ND, not detected. Data were obtained with biological tripli-
cates and shown as Mean and SD.
Fig. 4. Viral titration assay results provide a scale to interpret each read-out of virus titration in the context of VGE, infectious titre and actual capability of in vivo lesion formation.
8 N. Egawa et al. / EBioMedicine 63 (2021) 103177sequestered during anion-exchange chromatography (Fig. 6c),
while papillomavirus particles were only sequestered during cat-
ion-exchange chromatography, with 500 mM NaCl being required
for elution (Fig. 6d). OPA-glycine, but not OPA-lysine, effectively
blocked virus binding to the cation-exchange column, which sup-
ports the hypothesis that negatively charged molecules such as
OPA-glycine modify overall papillomavirus charge electrostatically
(Figs. 6d and 6e). These results may explain the comparable
effects of OPA and neutralised OPA (OPA-glycine) on in vitro HPV
infectivity reported recently [11,12], highlighting a need for
including appropriate neutralised negative controls that do not
bind to the virus when evaluating disinfectants.3.6. In vivo efficacy of disinfectants in controlling papillomavirus
transmission
In order to evaluate the efficacy of disinfectants on physiologically
relevant in vivo transmission, extracted MmuPV1 was incubated with
OPA or hydrogen peroxide, both of which achieved a >4-log10 reduc-
tion in infectious titre (Fig. 7a), with no lesion development, even at
16 weeks post-infection. Hypochlorite showed at least a 3-log10
reduction but failed to achieve complete inhibition, with efficacy
improving at higher concentration (5,000 ppm). 70% ethanol did not
inhibit disease formation in vivo (Fig. 7a), similar to the in vitro results
shown in Fig. 5. Next, we evaluated the efficacy of disinfectants
Fig. 6. OPA-glycine disrupts the electrostatic charge of virus particles and inhibits infection
(a) Virus infectivity (E1^E4 viral gene transcripts or reporter gene activity) of HPV18, MmuPV1 and PsV in HaCaT cells following incubation with OPA-glycine and OPA-lysine.
ND, not detected. (b) Schematic representation of the reaction of OPA with glycine and lysine. Estimated pI and charge at pH 7.4 are shown. (c) Relative amount of cation-exchange
(cation) or anion-exchange (anion) membrane-sequestered OPA-glycine and OPA-lysine during ion-exchange chromatography. AU, arbitrary unit. (d) Measurement of infectious
dose? of membrane-sequestered PsV, and PsV plus OPA-glycine or OPA-lysine. (e) Relative VGE of membrane-sequestered HPV18 and MmuPV1 in the presence of OPA-glycine or
OPA-lysine. All data were shown as Mean and SD and obtained with biological triplicates.
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OPA, hydrogen peroxide and hypochlorite all showed at least a 3-
log10 reduction in infectious titre, complete inhibition was never
seen, with 1000 ppm hypochlorite showing the lowest efficacy. Simi-
larly, 70% ethanol showed no reduction in virus infectivity (Fig. 7c).
In contrast to what was seen with OPA-glycine, the neutralised disin-
fectants had either little or no effect on disease formation in vivo
(Figs. 7b and d), which most likely reflects the extended kinetics of
the in vivo infection process (days rather than hours), and the pres-
ence of tissue proteins at the wound site, which may competitively
dissociate molecules such as OPA-glycine that bind electrostatically
to the virion surface. These results, using an in vivo transmission
model with ‘naturally produced’ papillomavirus, support our in vitro
studies showing that the OPA, hypochlorite and hydrogen peroxide
all show sufficient effectiveness for PV disinfection, while 70% etha-
nol was found to be ineffective. Furthermore, whether the virions
were cell-free or present with exfoliating cells had a significant
impact on susceptibility to disinfection, suggesting that being shed
within an anuclear squame confers an important survival advantage
on the virus, protecting it against both desiccation and disinfection.
The study highlights the need to use physiologically relevant modelsfor the evaluation of virus control measures and emphasises the
importance of combining disinfection with other decontamination
methods such as physical cleaning.
4. Discussion
4.1. Characterization of HPV titres and types in clinical lesions
Several reports have highlighted a risk of nosocomial high-risk
HPV transmission during cervical examination and treatment [5,6],
however, there has been no quantitative assessment of infectious
virus titres at the cervix of patients with HPV, or the risk of disease
transmission through fomite contact. To examine this, we quantified
for the first time the level of virus production from the lesion surface
of patients with cervical lesions (Fig. 1), and have used this informa-
tion to cover a clinically relevant range of virus doses in our experi-
ments (Fig. 4). There was significant variation in viral titres recovered
on the patch across lesions (ranging from 0.34 VGE/mm2 to
9.72 £ 108 VGE/mm2) with a trend for lower viral titres in individuals
presenting with HSIL, which typically represent abortive or non-pro-
ductive infections. LSIL, and heterogeneous lesions where HSIL was
Fig. 7. Evaluation of efficacy of disinfectants using MmuPV1 in vivo infection assay
Proportion of lesions formed at infected sites over a 16-week observation period following inoculation with cell-free MmuPV1 previously incubated with (a) disinfectant or (b)
neutralised disinfectant, or MmuPV11 with exfoliating cells on fomite previously incubated with (c) disinfectant or (d) neutralised disinfectant. The numbers of sites of inoculation
(N) and mice in each group are shown.
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their surface. Interestingly, a subset of LSIL showed only very low
virus titres, which is compatible with previous reports suggesting
that a proportion of lesions in this category may be non-productive
[27], or lack a HPV causal association (See Fig. 1c) [28].
4.2. In vitro to in vivo correlation of papillomavirus disease formation
Prior to this work, the extent to which in vitro infectivity assays
predict the risk of virus transmission in vivo was not known. Simi-
larly, an infectious dose has not yet been linked to the risk of disease
formation for any papillomavirus, and indeed there are limited
opportunities to gather such in vivo data, other than from mice.
Because of this, and because MmuPV1 and HPV show similar in vitroinfectivity profiles, we sought to relate virus dose (VGE and infec-
tious) to the kinetics of in vivo disease development following
MmuPV1 infection. We have adapted recombinant PsV technologies
and organotypic raft culture systems and used these alongside a
MmuPV1 in vivo infection model to obtain high concentrations of
infectious papillomavirus particles (Figs. 2 and 3). Laboratory-based
in vitro and in vivo systems were used to quantify virus titre, and to
provide a comprehensive evaluation of papillomavirus infectivity
and susceptibility to disinfectants and their subsequent ability to
drive in vivo disease formation (Fig. 4). On the basis of the data pre-
sented herein, in which an in vitro to in vivo correlation has been
established for disinfection, it appears that the two infectivity assays
are sufficient to provide an in vitro standard for evaluating the effi-
cacy of agents such as disinfectants that may be used to control the
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of infected cells and infectious virus particles, and provides insights
into the rate of new lesion formation, whereas the transcript quanti-
tation assay provides a high throughput method to evaluate the rela-
tive extent of viral transcription within a group of cells exposed to
different conditions.
The development of the MmuPV1 model allows additional in vivo
validation using native virus extracted after productive infection of
mice. The preparation of high titre virus stocks from the MmuPV1
model is more straightforward than from the HPV18/16 organotypic
raft system, and as both MmuPV1 and HPV18 showed similar behav-
iour in in vitro assays, it appears that MmuPV1 can be used as a con-
venient surrogate to study HPV transmission and infection. Such in
vivo infection assays can be modified to mimic the natural transmis-
sion and infection route, including the ‘worst-case scenario’, where
direct PV inoculation occurs at the scarification site in an immuno-
compromised host.4.3. Role of exfoliating squames in papillomavirus transmission and
disease formation
The results obtained in the mouse model highlight the importance
of evaluating the role of squames in viral disinfectant susceptibility
and transmission (Figs. 3 and 7). During natural transmission, the
virus is not shed as free virions, but rather is released from the sur-
face of the skin in exfoliating cells or squames [26]. Importantly, virus
collected along with exfoliating cells showed greater resistance to
environmental stresses, such as desiccation and oxidation, and was
found to persist for at least a year with only a minimal drop in infec-
tivity. Importantly for this study, virus released in exfoliating cells
showed a significant increase in disinfectant resistance when com-
pared to laboratory purified virions and PsV, which should be
addressed in future studies of papillomavirus transmission and disin-
fection resilience. Among the disinfectants we tested here, OPA, and
comparably hydrogen peroxide, showed the highest efficacy for virus
inactivation in exfoliating cells (Fig. 7). In this context, it is worth not-
ing that cells in the upper epithelial layers, where virus assembly
occurs, contain very high levels of the viral E4 protein, which assem-
bles into amyloid-like fibres and is thought to contribute to virus
release, transmission, survival, and most probably also disinfectant
resistance [10]. The currently accepted protocols, which use cell-free
virus in the presence of simple organic load or ‘soil’ to evaluate the
viricidal activity of chemical disinfectants [8,11,12], do not fully eval-
uate the role of the abundant E4 protein and the contents of exfoliat-
ing cells, which will include components of the cornified envelope
along with some structural keratins and filaggrin.4.4. Efficacy of high-level disinfectants across model systems
In contrast to the previously published results by Meyers et al.
[11,12], our results clearly show that papillomaviruses are suscepti-
ble to both conventional aldehyde-, chlorine- and oxidant-based dis-
infectants, but are resistant to alcohol-based disinfection, although
PsVs show partial susceptibility to the latter. This difference is
thought to be due to the difference in maturation of the virus particle,
and specifically the extent of cross-linking between L1 viral capsid
proteins, which is lower in recombinant PsVs and quasivirions when
compared to raft-derived or native virions [29,30]. This work focused
solely on the effectiveness of disinfectants alone, particularly in com-
parison to OPA, whereas protection and disinfection in clinical prac-
tice involves the use of barriers to infection, such as disposable
covers for transvaginal probes, along with mechanical cleaning sys-
tems. Given the high degree of HPV inactivation following incubation
with disinfectants alone, and the additional physical cleaning steps
that go into high-level disinfection[31], the results demonstrate thatthere is likely to be a minimal risk of HPV transmission following
high-level disinfection, which should be addressed in future studies.
4.5. Importance of the choice of model systems and appropriate controls
We have also shown that PV particles are positively charged at
physiological pH, and that OPA-glycine, but not OPA-lysine, can affect
the charge of the virus particle. The charge of the virus is, in general,
considered to play an important role in the virus-host cell interaction
prior to infection. For example, cationic polymers are typically used
to increase the efficiency of retrovirus infection in vitro, and are con-
sidered to create an electrostatic environment that promotes the
optimum interaction between negatively charged retrovirus and
heparan sulfate proteoglycans (HSPGs) [32]. The binding to HSPGs is
also considered an important step in HPV infection [33]. Taking these
points together, we hypothesise that negatively charged OPA-glycine
neutralises the positive charge of the virus particle and inhibits PV
binding to the host cells in our in vitro infection model. Negatively
charged carrageenan, indeed, is known to inhibit PV infection [15].
Glycine is used as a general OPA neutraliser, and was chosen in the
previously published reports by Meyers et al.[11,12]. In our in vitro
and in vivo infection model systems however, OPA-glycine showed
distinctive effects on papillomavirus infectivity, probably reflecting
the different kinetics of the infection process between in vitro and
in vivo infection models (Figs. 6a and 7). Taking these results
and the work presented in the companion manuscript by the lab
of Dr Michelle Ozbun together (https://doi.org/10.1016/j.
ebiom.2020.103165) [34], it is clear that the proper evaluation of
virus infectivity and the efficacy of disinfectants requires a clear
understanding of the characteristics of the infection models (in vitro
and in vivo), and the source of virus (cell-free virus, virus with exfoli-
ating cells and/or clinically sourced virus), along with the appropriate
use of validated controls (e.g. for virus titre, contact time, concerta-
tion of disinfectant and the choice of neutralisers).
5. Conclusion
The results herein can provide confidence to patients and the
healthcare community that there is a minimal risk for transmission
of HPV from medical devices following high-level disinfection with
aldehyde-based disinfectants. The methods that have been devel-
oped, which combine quantification of viral load in patient lesions,
assessment of viral-titre response for infection in cell culture, and
dynamics of disease formation in vivo, provide a helpful framework
for evaluating the dynamics of viral transmission, susceptibility for
disinfection and their implications for clinical transmission.
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